MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


Midatech Pharma says full-year revenue up 29% as expected

StockMarketWire.com

Oncology-focused group Midatech Pharma said it expected its revenue for the full year to increase in line with expectations.

Based on unaudited results, revenue was expected to be at least £7.4m, the company said, up 29% on the previous year.

The company's US operation also reached break-even in the second half, it added.

At 31 December, the company's cash balance was £13.2m, down from £17.6m a year earlier, but also in line with market expectations.

'With our two lead candidates now approved to enter the clinic, and our established US commercial presence in the US delivering consistent growth, 2017 was a significant year in the group's development and 2018 shows great promise,' chief executive Jim Phillips said.

'Following the loan agreement signed at the beginning of this year, and with rigorous cost containment, Midatech is funded to support progression towards these and other value-driving product milestones and we eagerly await various value inflections points in 2018.'

At 8:19am: (LON:MTPH) Midatech Pharma Plc share price was 0p at 36.5p


Story provided by StockMarketWire.com